Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELITRA: CHF 5259 Add-on to QVAR in Uncontrolled Asthma
NCT02296411Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium bromide in asthma (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Forced Expiratory Volume in the first second Area Under the Curve between time 0 and 12 hours Normalized by Time at Day 42. Started Nov 2014; status: completed.
02
Drugs
glycopyrronium bromide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02296411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296411.